[Skip to Content]
[Skip to Content Landing]
Other Articles
September 25, 1937


JAMA. 1937;109(13):1036-1037. doi:10.1001/jama.1937.92780390002013a

In spite of the intensive use of sulfanilamide in the last year as a chemotherapeutic agent in beta-hemolytic streptococcus infections, clinical reports have noted a relatively low incidence of untoward reactions. Our observations of more than 300 patients in the erysipelas wards of Bellevue Hospital (service of Dr. John Nelson), treated with sulfanilamide, are in substantial agreement with this. The occurrence of dizziness, mental confusion, lassitude and mild cyanosis was not uncommon with patients receiving large doses of the drug, but this in no way interfered with the therapy or its effects. Of this entire group, dermal reactions in the form of toxic erythema appeared in only one patient. This was a banal type of toxic erythema, evanescent and of nondescript character, and might well have been a consequence of the infection itself.

The more recent use of sulfanilamide in ambulatory cases of nonstreptococcic infection appears to supply

First Page Preview View Large
First page PDF preview
First page PDF preview